Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
, 3 (4), e13

Serotonin and GI Disorders: An Update on Clinical and Experimental Studies

Affiliations

Serotonin and GI Disorders: An Update on Clinical and Experimental Studies

Marcus Manocha et al. Clin Transl Gastroenterol.

Abstract

The gastrointestinal (GI) tract is the largest producer of serotonin (5-hydroxytryptamine (5-HT)) in the body, and as such it is intimately connected with GI function and physiology. 5-HT produced by enterochromaffin (EC) cells is an important enteric mucosal signaling molecule and has been implicated in a number of GI diseases, including inflammatory bowel disease and functional disorders such as irritable bowel syndrome. This review will focus on what is known of basic 5-HT physiology and also on the emerging evidence for its novel role in activation of immune response and inflammation in the gut. Utilizing pubmed.gov, search terms such as "5-HT," "EC cell," and "colitis," as well as pertinent reviews, were used to develop a brief overview of EC cell biology and the association between 5-HT and various GI disorders. It is the aim of this review to provide the readers with an update on EC cell biology and current understanding on the role of 5-HT in GI disorders specifically in inflammatory conditions.

Figures

Figure 1
Figure 1
Modulation of EC cell biology by immune cells and modulation of immune cells by 5-HT in GI disease. The role of 5-HT in modulating the innate and adaptive immune system can vary by cell type. 5-HT has been shown to enhance phagocytosis in murine macrophages. In addition, 5-HT can increase chemotaxis of dendritic cells and promote the release of the Th2-attracting chemokine CCL22 while decreasing the Th1 chemokine CXCL10. Finally 5-HT has a proliferative effect on CD4+ T cells, which when coupled with 5-HT effect on dendritic cells create a more permissive environment for a Th2 immune response. CD4+ T cells particularly Th2 cytokines, such as interleukin-13, in turn may influence on EC cell biology, 5-HT synthesis, and 5-HT release.

Similar articles

See all similar articles

Cited by 39 articles

See all "Cited by" articles

References

    1. Rapport MM, Green AA, Page IH. Serum vasoconstrictor, serotonin; isolation and characterization. J Biol Chem. 1948;176:1243–1251. - PubMed
    1. Erspamer V. Historical introduction: the Italian contribution to the discovery of 5-hydroxytryptamine (enteramine, serotonin) J Hypertens Suppl. 1986;4:S3–S5. - PubMed
    1. Coates MD, Mahoney CR, Linden DR, et al. Molecular defects in mucosal serotonin content and decreased serotonin reuptake transporter in ulcerative colitis and irritable bowel syndrome. Gastroenterology. 2004;126:1657–1664. - PubMed
    1. Magro F, Vieira-Coelho MA, Fraga S, et al. Impaired synthesis or cellular storage of norepinephrine, dopamine, and 5-hydroxytryptamine in human inflammatory bowel disease. Dig Dis Sci. 2002;47:216–224. - PubMed
    1. Miwa J, Echizen H, Matsueda K, et al. Patients with constipation-predominant irritable bowel syndrome (IBS) may have elevated serotonin concentrations in colonic mucosa as compared with diarrhea-predominant patients and subjects with normal bowel habits. Digestion. 2001;63:188–194. - PubMed

LinkOut - more resources

Feedback